Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain

This study is currently recruiting participants.
Verified August 2012 by Shahid Beheshti University
Information provided by (Responsible Party):
saranaz azari-marhabi, Shahid Beheshti University
ClinicalTrials.gov Identifier:
First received: August 4, 2012
Last updated: August 6, 2012
Last verified: August 2012

tempromandibuar disorders are a group of heterogenous pathologies affecting temporomandibular joint,muscles or both.in more than 90%of cases muscles are the origin of pain.TMDs cause pain,movement disability and deficit in quality of life.in more than 90%of cases pain is the major complaint.we run this investigation to find the analgesic effct of low level laser therapy versus pharmacotherapy with naproxen in improving pain.

Condition Intervention Phase
Radiation: low level laser therapy
Drug: Naproxen
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Phase 1 Study of Low Level Laser Therapy Versus Naproxen

Resource links provided by NLM:

Further study details as provided by Shahid Beheshti University:

Primary Outcome Measures:
  • reduction of paim measured by VAS [ Time Frame: 1 month ] [ Designated as safety issue: No ]
    VAS is visual analogue scale

Estimated Enrollment: 40
Study Start Date: June 2012
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low level laser therapy
this arm recieves low level laser therapy treatment for 12 sessions.
Radiation: low level laser therapy
Experimental: naproxen
this arm takes naproxen 500 mg twice daily for 3weeks
Drug: Naproxen


Ages Eligible for Study:   15 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • patients with TMD affecting masticatory muscles

Exclusion Criteria:

  • systemic disease
  • GI problem
  • pregnancy
  • epidermal cancer
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01659372

Contact: saranaz azari marhabi, post graduate student 00989190129151 saranazazari@yahoo.com

Iran, Islamic Republic of
Shahid Beheshti University Not yet recruiting
Tehran, Iran, Islamic Republic of, 1983969411
Shahid Beheshti University Recruiting
Tehran, Iran, Islamic Republic of, 1983969411
Contact: saranaz azari-marhabi, doctor    00989190129151    saranazazari@yahoo.com   
Principal Investigator: saranaz azari-marhabi, resident         
Sponsors and Collaborators
Shahid Beheshti University
  More Information

No publications provided

Responsible Party: saranaz azari-marhabi, oral medicine resident, Shahid Beheshti University
ClinicalTrials.gov Identifier: NCT01659372     History of Changes
Other Study ID Numbers: ABT-1233-RV
Study First Received: August 4, 2012
Last Updated: August 6, 2012
Health Authority: Iran: Ministry of Health

Keywords provided by Shahid Beheshti University:
temporomandibular disorder
myofascial pain syndrome

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 15, 2014